Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of “Hold” from Brokerages

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has been assigned a consensus recommendation of “Hold” from the five analysts that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $3.67.

A number of equities research analysts recently commented on the stock. Leerink Partners reaffirmed a “market perform” rating and issued a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. StockNews.com started coverage on Lexicon Pharmaceuticals in a research report on Saturday. They set a “sell” rating on the stock. Piper Sandler cut their price target on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday, March 28th.

Institutional Trading of Lexicon Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC grew its holdings in Lexicon Pharmaceuticals by 28.9% during the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock valued at $78,291,000 after buying an additional 11,179,919 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Lexicon Pharmaceuticals by 630.7% during the fourth quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company’s stock valued at $6,638,000 after acquiring an additional 7,758,371 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its holdings in Lexicon Pharmaceuticals by 301.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company’s stock worth $5,582,000 after acquiring an additional 5,676,021 shares during the period. Nantahala Capital Management LLC lifted its stake in Lexicon Pharmaceuticals by 186.6% in the 4th quarter. Nantahala Capital Management LLC now owns 6,604,150 shares of the biopharmaceutical company’s stock worth $4,877,000 after purchasing an additional 4,300,000 shares in the last quarter. Finally, Tang Capital Management LLC boosted its holdings in Lexicon Pharmaceuticals by 750.3% in the 4th quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company’s stock valued at $628,000 after purchasing an additional 750,268 shares during the period. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Trading Up 23.5 %

Shares of Lexicon Pharmaceuticals stock opened at $0.52 on Tuesday. The firm has a market cap of $127.40 million, a PE ratio of -0.69 and a beta of 1.02. Lexicon Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $2.45. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The stock has a fifty day moving average price of $0.56 and a 200-day moving average price of $0.94.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. The business had revenue of $26.55 million during the quarter, compared to the consensus estimate of $6.48 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. Equities research analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.